SPAG5 and breast cancer: We considered that SPAG5 was correlated with mTOR signaling pathway activity during breast cancer treatment [2], and the cross-talk between the estrogen receptor and mTOR signaling pathway, the most well-known mechanism of endocrine resistance, led to poor prognosis of patients [29].